Generation of Specific Aptamers
© 2024. The Author(s), under exclusive license to Springer Science+Business Media, LLC, part of Springer Nature..
Nucleic acid aptamers are therapeutic agents consisting of short single-strand DNA or RNA oligonucleotides, which have the ability to bind to target therapeutic molecules with high affinity and specificity and have been developed as potent drugs for the treatment of rheumatoid arthritis. Aptamers have unique and advantageous features over antibodies, such as superior affinity with nano- or pico-molar dissociation constants and ease of chemical synthesis, modification, and inactivation by designing antisense sequences. In this chapter, using a DNA-oligonucleotide pool, the technology of proteoliposome-systematic evolution of ligands by exponential enrichment (SELEX) is introduced. By using this technique, potential therapeutic agents with high affinity and specificity could be obtained.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:2766 |
|---|---|
| Enthalten in: |
Methods in molecular biology (Clifton, N.J.) - 2766(2024) vom: 25., Seite 129-137 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Liu, Shuang [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Antibodies |
|---|
| Anmerkungen: |
Date Completed 26.01.2024 Date Revised 26.01.2024 published: Print Citation Status MEDLINE |
|---|
| doi: |
10.1007/978-1-0716-3682-4_13 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM367613018 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM367613018 | ||
| 003 | DE-627 | ||
| 005 | 20240126232238.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240125s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1007/978-1-0716-3682-4_13 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1271.xml |
| 035 | |a (DE-627)NLM367613018 | ||
| 035 | |a (NLM)38270872 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Liu, Shuang |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Generation of Specific Aptamers |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 26.01.2024 | ||
| 500 | |a Date Revised 26.01.2024 | ||
| 500 | |a published: Print | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © 2024. The Author(s), under exclusive license to Springer Science+Business Media, LLC, part of Springer Nature. | ||
| 520 | |a Nucleic acid aptamers are therapeutic agents consisting of short single-strand DNA or RNA oligonucleotides, which have the ability to bind to target therapeutic molecules with high affinity and specificity and have been developed as potent drugs for the treatment of rheumatoid arthritis. Aptamers have unique and advantageous features over antibodies, such as superior affinity with nano- or pico-molar dissociation constants and ease of chemical synthesis, modification, and inactivation by designing antisense sequences. In this chapter, using a DNA-oligonucleotide pool, the technology of proteoliposome-systematic evolution of ligands by exponential enrichment (SELEX) is introduced. By using this technique, potential therapeutic agents with high affinity and specificity could be obtained | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Aptamer | |
| 650 | 4 | |a PCR | |
| 650 | 4 | |a Proteoliposome | |
| 650 | 4 | |a SELEX | |
| 650 | 4 | |a Single-strand DNA | |
| 650 | 7 | |a Antibodies |2 NLM | |
| 650 | 7 | |a DNA, Single-Stranded |2 NLM | |
| 650 | 7 | |a Oligonucleotides |2 NLM | |
| 700 | 1 | |a Suzuki, Yasuyuki |e verfasserin |4 aut | |
| 700 | 1 | |a Inui, Makoto |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Methods in molecular biology (Clifton, N.J.) |d 1984 |g 2766(2024) vom: 25., Seite 129-137 |w (DE-627)NLM074849794 |x 1940-6029 |7 nnns |
| 773 | 1 | 8 | |g volume:2766 |g year:2024 |g day:25 |g pages:129-137 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1007/978-1-0716-3682-4_13 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 2766 |j 2024 |b 25 |h 129-137 | ||